Physicians' Academy for Cardiovascular Education

Diabetes & CVD

Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.

The cardiology challenge to manage CV risk in diabetes

10' education - Sep. 9, 2020 - Prof. Nikolaus Marx, MD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD

Succes with SGLT2 inhibitor in HFrEF for all three end points

3' education - Aug. 29, 2020 - Milton Packer, MD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

3rd Groningen Heart failure symposium: How to implement the newest HF therapies?

10' education - Aug. 25, 2020 - Prof. Dirk Jan van Veldhuisen, MD and prof. Adriaan Voors, MD

Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?

10' education - July 21, 2020 - Prof. Johannes Mann, MD

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Mark Cooper, MD

Obesity as a risk factor for severity of COVID-19: multiple potential mechanisms

5' education - May 1, 2020 - Prof. Naveed Sattar, MD

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD

More insight into daily clinical practice and more collaboration needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD

Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

Barriers to implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM

5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

FDA Fast Track designation for SGLT2i in patients with and without T2DM after acute MI

News - Sep. 17, 2020

The FDA has granted Fast Track designation for empagliflozin to reduce hospitalization for HF and mortality in patients with and without T2DM following an acute MI.

Expert consensus on use of SGLT2i and GLP-1RAs for CV risk reduction in T2DM

News - Sep. 15, 2020

This 2020 expert consensus decision pathway (ECDP) provides practical guidance on the use of SGLT2i and GLP-1RAs for reducing the risk of CVD in patients with T2DM.

Presence of the obesity paradox in a cohort of pre-diabetes and T2DM patients

Literature - Sep. 15, 2020 - Doehner W, et al. - Eur Heart J 2020

Participants who were overweight or obese had lower risk of total and CV mortality in a cohort of prediabetes and T2DM patients from the ORIGIN trial.

ARNI reduces adverse renal events and slows kidney function decline in HFpEF patients

Literature - Sep. 15, 2020 - Mc Causland FR et al. - Circulation. 2020

This substudy of the PARAGON-HF trial demonstrated that in HFpEF patients, sacubitril/valsartan reduced the risk of a composite of renal outcomes and attenuated decline in kidney function compared to valsartan alone.

The cardiology challenge to manage CV risk in diabetes

10' education - Sep. 9, 2020 - Prof. Nikolaus Marx, MD
Prof. Marx discusses evidence on how CV risk in diabetes can be reduced by new diabetes agents and current guideline recommendations to manage patients with diabetes and high CV risk.

Prof. Marx discusses evidence on how CV risk in diabetes can be reduced by new diabetes agents and current guideline recommendations to manage patients with diabetes and high CV risk.

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD
Although there are differences between the EMPEROR-Reduced and DAPA-HF trials with regard to secondary end points, Milton Packers wants to emphasize the class effects of SGLT2 inhibitors.

ESC 2020 Although there are differences between the EMPEROR-Reduced and DAPA-HF trials with regard to secondary end points, Milton Packers wants to emphasize the class effect of SGLT2 inhibitors.

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD
Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.

Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.

SGLT2i reduces HF hospitalizations in T2DM patients with ASCVD

News - Aug. 31, 2020

ESC 2020 Ertugliflozin reduced time to first HF hospitalization, total HF hospitalizations and total HF hospitalizations/CV death events in T2DM patients with ASCVD.

Combining BMI and polygenic score to predict lifetime risk of diabetes

News - Aug. 31, 2020

ESC 2020 Using data of the UK Biobank, this study showed that BMI and a polygenic score for diabetes have independent and additive effect on lifetime risk of diabetes, and should be used in combination for risk prediction.

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD
After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.

ESC 2020 After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.

SGLT2i reduces risk of kidney failure, CV death or HF hospitalization, and all-cause mortality in CKD

News - Aug. 30, 2020

ESC 2020 The DAPA-CKD trial showed that dapagliflozin significantly reduced the risk of kidney failure, CV death or HF hospitalization, and all-cause mortality in patients with CKD, with and without T2DM, compared to placebo.

Succes with SGLT2 inhibitor in HFrEF for all three end points

3' education - Aug. 29, 2020 - Milton Packer, MD
Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.

ESC 2020 Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.